TO THE EDITOR
I read with great attention the article by Saghaei et al. in a recent issue of your esteemed journal [1]. The article is highly interesting and thought-provoking. Of note, the past few years have seen the emergence of nimesulide as an in vitro agent with significant anti-carcinogenic properties, in addition to its primary role as an analgesic.
For example, nimesulide attenuates mammalian target of rapamycin (mTOR) signaling and thereby inhibits tissue growth in colorectal carcinomas [2]. Similarly, reduced proliferation is seen in aromatase inhibitor-insensitive breast cancer cells following administration of the nimesulide analogue JCC76 [3]. Nimesulide also enhances the effects of radiotherapy in lung carcinomas through intensification of caspase-3 and caspase-8 activation [4]. Similarly, nimesulide attenuates tumor growth in pancreatic carcinomas by inhibiting vascular endothelial growth factor (VEGF) [5].
Similar growth inhibitory effects are seen in gastric carcinomas. These effects are mediated by increased secretion of TNF-alpha secondary to nimesulide administration [6].
Nimesulide also downregulates the aquaporin-3 gene and attenuates the expression of the KSHV gene, resulting in apoptosis in primary effusion lymphomas [7]. In addition, nimesulide inhibits tumor growth in hepatocellular carcinomas. The apoptotic effect of nimesulide in hepatocellular carcinomas is augmented by the mDRA-6 monoclonal antibody [6].
Nimesulide must be used with care because of the attendant risk of hepatotoxicity [8].
Clearly, nimesulide demonstrates significant anti-neoplastic effects in vitro. Additional in vivo studies are needed to further elaborate and fully harness the anti-carcinogenic properties of nimesulide.
References
- 1.Saghaei E, Moini Zanjani T, Sabetkasaei M, Naseri K. Enhancement of antinociception by co-administrations of nefopam, morphine, and nimesulide in a rat model of neuropathic pain. Korean J Pain. 2012;25:7–15. doi: 10.3344/kjp.2012.25.1.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Zhang YJ, Bao YJ, Dai Q, Yang WY, Cheng P, Zhu LM, et al. mTOR signaling is involved in indomethacin and nimesulide suppression of colorectal cancer cell growth via a COX-2 independent pathway. Ann Surg Oncol. 2011;18:580–588. doi: 10.1245/s10434-010-1268-9. [DOI] [PubMed] [Google Scholar]
- 3.Zhong B, Cai X, Yi X, Zhou A, Chen S, Su B. In vitro and in vivo effects of a cyclooxygenase-2 inhibitor nimesulide analog JCC76 in aromatase inhibitors-insensitive breast cancer cells. J Steroid Biochem Mol Biol. 2011;126:10–18. doi: 10.1016/j.jsbmb.2011.03.018. [DOI] [PubMed] [Google Scholar]
- 4.Kim BM, Won J, Maeng KA, Han YS, Yun YS, Hong SH. Nimesulide, a selective COX-2 inhibitor, acts synergistically with ionizing radiation against A549 human lung cancer cells through the activation of caspase-8 and caspase-3. Int J Oncol. 2009;34:1467–1473. [PubMed] [Google Scholar]
- 5.Ambike V, Adsule S, Ahmed F, Wang Z, Afrasiabi Z, Sinn E, et al. Copper conjugates of nimesulide Schiff bases targeting VEGF, COX and Bcl-2 in pancreatic cancer cells. J Inorg Biochem. 2007;101:1517–1524. doi: 10.1016/j.jinorgbio.2007.06.028. [DOI] [PubMed] [Google Scholar]
- 6.Liu YJ, Ma YF, Zhang J, Zhao YP, Bai HL, Li SL. Synergistic lethal effect of mDRA-6 and nimesulide on human hepatocellular cancer cell line SMMC-7721. Ai Zheng. 2008;27:374–378. [PubMed] [Google Scholar]
- 7.Paul AG, Sharma-Walia N, Chandran B. Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma. PLoS One. 2011;6:e24379. doi: 10.1371/journal.pone.0024379. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Nimesulide: patients still exposed to a risk of severe hepatitis. Prescrire Int. 2011;20:125–126. [PubMed] [Google Scholar]